Literature DB >> 7356903

Effect of cimetidine on the absorption of orally administered tetracycline.

P Fisher, F House, P Inns, P J Morrison, H J Rogers, I D Bradbrook.   

Abstract

1 Six healthy female subjects received orally two 250 mg tetracycline tablets either with 400 mg cimetidine or placebo. In a separate experiment six healthy female volunteers received 500 mg tetracycline as a suspension on the fifth day of a 6 day regime of 400 mg cimetidine or placebo, 8 hourly and at bedtime. 500 mg tetracycline as tablets was also given with cimetidine only. 2 Following a single dose of cimetidine the mean peak tetracycline plasma concentration was significantly reduced by 1.2 microgram/ml and the area under the plasma concentration, time curve was decreased by 40%. The 72 h urinary tetracycline excretion was diminished by approximately 30%. 3 Tetracycline had no effect on the plasma concentration, time profile of cimetidine. 4 Administration of 400 mg cimetidine 8 hourly and at night for 6 days and dosing with 500 mg tetracycline as tablets or suspension on the fifth day produced no alteration in tetracycline kinetics. 5 It was concluded that under clinical circumstances it is unlikely that cimetidine produces a clinically significant alteration in tetracycline absorption or disposition. 6 The bioavailability of tetracycline from tablets and suspension was found to be similar (31.2% and 36.9% of the dose excreted in the urine over 72 h). 7 The mean renal clearance of tetracycline was 83.8 ml/min (95% confidence interval +/- 9.2 ml/min) and was unaltered by cimetidine treatment.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7356903      PMCID: PMC1429866          DOI: 10.1111/j.1365-2125.1980.tb05826.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  18 in total

1.  Biological availability and in vitro release from oral oxytetracycline and tetracycline preparations.

Authors:  T Bergan; B Oydvin; I Lunde
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1973

2.  Curve fitting by spline and Akima methods: possibility of interpolation error and its suppression.

Authors:  J Fried; S Zietz
Journal:  Phys Med Biol       Date:  1973-07       Impact factor: 3.609

3.  Decrease of tetracycline absorption in man by sodium bicarbonate.

Authors:  W H Barr; J Adir; L Garrettson
Journal:  Clin Pharmacol Ther       Date:  1971 Sep-Oct       Impact factor: 6.875

4.  Influence of different pharmaceutical forms on the efficiency of tetracycline.

Authors:  R Helmi; A Elian; M Mustafa; H I el-Sayed; S el-Razeky
Journal:  J Egypt Med Assoc       Date:  1969

5.  Assessment of the biologic availability of tetracycline products in man.

Authors:  W H Barr; L M Gerbracht; K Letcher; M Plaut; N Strahl
Journal:  Clin Pharmacol Ther       Date:  1972 Jan-Feb       Impact factor: 6.875

6.  pH-Partition behavior of tetracyclines.

Authors:  J L Colaizzi; P R Klink
Journal:  J Pharm Sci       Date:  1969-10       Impact factor: 3.534

7.  Cimetidine in the treatment of gastric ulcer: review and commentary.

Authors:  J W Freston
Journal:  Gastroenterology       Date:  1978-02       Impact factor: 22.682

8.  Effect of histamine H2-receptor blockade on gastric emptying and serum gastrin in man.

Authors:  J A Forrest; R C Heading; J Park; D C Carter; J Lennon; G Lidgard; D J Shearman
Journal:  Scott Med J       Date:  1976-01       Impact factor: 0.729

9.  Tetracycline absorption in elderly patients with achlorhydria.

Authors:  P A Kramer; D J Chapron; J Benson; S A Mercik
Journal:  Clin Pharmacol Ther       Date:  1978-04       Impact factor: 6.875

10.  Bioavailability of tetracycline and doxycycline in fasted and nonfasted subjects.

Authors:  P G Welling; P A Koch; C C Lau; W A Craig
Journal:  Antimicrob Agents Chemother       Date:  1977-03       Impact factor: 5.191

View more
  10 in total

1.  Reduced steady-state plasma concentrations of chlorpromazine and indomethacin in patients receiving cimetidine.

Authors:  C A Howes; T Pullar; I Sourindhrin; P C Mistra; H Capel; D H Lawson; W J Tilstone
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

Review 2.  Drug interactions with cimetidine.

Authors:  A Somogyi; R Gugler
Journal:  Clin Pharmacokinet       Date:  1982 Jan-Feb       Impact factor: 6.447

3.  Effects of cimetidine and absorption of tetracycline.

Authors:  M Garty; A Hurwitz
Journal:  Br J Clin Pharmacol       Date:  1980-10       Impact factor: 4.335

4.  Concurrent administration of cimetidine and enteric-coated prednisolone: effect on plasma levels of prednisolone.

Authors:  P J Morrison; H J Rogers; I D Bradbrook; C Parsons
Journal:  Br J Clin Pharmacol       Date:  1980-07       Impact factor: 4.335

5.  Evaluation of the Correspondence between the Concentration of Antimicrobials Entering Sewage Treatment Plant Influent and the Predicted Concentration of Antimicrobials Using Annual Sales, Shipping, and Prescriptions Data.

Authors:  Takashi Azuma; Takashi Nakano; Ryuji Koizumi; Nobuaki Matsunaga; Norio Ohmagari; Tetsuya Hayashi
Journal:  Antibiotics (Basel)       Date:  2022-04-01

6.  The effect of intravenous cimetidine on the absorption of orally administered diazepam and lorazepam.

Authors:  W A McGowan; J W Dundee
Journal:  Br J Clin Pharmacol       Date:  1982-08       Impact factor: 4.335

Review 7.  [Effect of histamine H2-receptor antagonists on the hepatic elimination of drugs].

Authors:  U Klotz; I Reimann
Journal:  Klin Wochenschr       Date:  1983-07-01

8.  Cimetidine-phenytoin interaction: effect on serum phenytoin concentration and antipyrine test.

Authors:  P J Neuvonen; R A Tokola; M Kaste
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

9.  Decreased systemic clearance of caffeine due to cimetidine.

Authors:  L J Broughton; H J Rogers
Journal:  Br J Clin Pharmacol       Date:  1981-08       Impact factor: 4.335

Review 10.  Adverse reactions and interactions with H2-receptor antagonists.

Authors:  J Penston; K G Wormsley
Journal:  Med Toxicol       Date:  1986 May-Jun
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.